Granite Bio

Basel, Switzerland

Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.

$70.0M raised

Apr 2025

Series B

Top Investors

Versant VenturesForbion Capital PartnersNovartis Venture FundSanofi Ventures

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Granite Bio raised?

Granite Bio has raised $70.0M in total funding. The most recent round was Series B. The last funding was announced in April 2025.

Who are Granite Bio's investors?

Granite Bio's investors include Versant Ventures, Forbion Capital Partners, Novartis Venture Fund, Sanofi Ventures.

Where is Granite Bio headquartered?

Granite Bio is headquartered in Basel, Switzerland.

What does Granite Bio do?

Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.

What stage is Granite Bio at?

Granite Bio is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 24, 2025.

MLA

"Granite Bio — Funding & Investors." VCBacked, April 24, 2025, https://www.vcbacked.co/company/granite-bio. Accessed June 9, 2026.

APA

VCBacked. (2025). Granite Bio — Funding & Investors. Retrieved June 9, 2026, from https://www.vcbacked.co/company/granite-bio

Wikipedia (cite web)

{{cite web |title=Granite Bio — Funding & Investors |url=https://www.vcbacked.co/company/granite-bio |website=VCBacked |access-date=June 9, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 24, 2025.